Bone Biologics Corp 8-K

What Happened
Bone Biologics Corporation (BBLG) filed an 8-K on March 13, 2026 disclosing a prospectus supplement for an at-the-market (ATM) offering that would allow the company to sell shares of its common stock with an aggregate market value of up to $1,064,000. Sales would be made from time to time through H.C. Wainwright & Co., LLC under the company’s existing At The Market Offering Agreement dated September 27, 2024, using the prospectus supplement dated March 13, 2026 and the base prospectus dated September 2, 2025, which are part of its Form S-3 shelf registration (File No. 333-288290).

Key Details

• Prospectus supplement filed: March 13, 2026 (covers ATM offering up to $1,064,000 aggregate market value).
• Sales agent: H.C. Wainwright & Co., LLC, under Sales Agreement dated September 27, 2024.
• Shelf registration: Form S-3 (File No. 333-288290), base prospectus dated September 2, 2025 (declared effective Sept 2, 2025).
• Prior sales: The company previously sold approximately $1.7 million of common stock under the same Sales Agreement using a prior registration statement (no longer effective).
• Legal opinion: Opinion as to legality for the $1,064,000 of shares filed as Exhibit 5.1 to this 8-K.

Why It Matters
This filing gives Bone Biologics the ability to raise capital over time by selling shares into the market (an ATM program) up to the stated aggregate value. For investors, ATM offerings can dilute existing holdings if shares are sold, and sales typically occur based on market conditions and company needs. The 8-K does not state any specific use of proceeds or indicate that sales have occurred—only that the company has refreshed its prospectus authority to sell up to the noted amount.